Clindamycin Dosing for Children
For children >1 month of age, use 20-40 mg/kg/day IV/IM divided every 6-8 hours (higher doses for severe infections), and 30-40 mg/kg/day orally divided every 6-8 hours; for neonates <1 month, use 15-20 mg/kg/day IV/IM divided every 8 hours.
Intravenous/Intramuscular Dosing
Children 1 Month to 16 Years
- Serious infections: 20-40 mg/kg/day divided into 3-4 equal doses 1
- More severe infections: Use the higher end of the dosing range (40 mg/kg/day) 1
- Alternative dosing by body surface area:
- Serious infections: 350 mg/m²/day
- More severe infections: 450 mg/m²/day 1
Neonates <1 Month
- Standard dose: 15-20 mg/kg/day divided into 3-4 equal doses 1
- Premature infants ≤32 weeks PMA: 5 mg/kg every 8 hours 1
- Term infants 32-40 weeks PMA: 7 mg/kg every 8 hours 1
The lower dosing in premature neonates reflects significantly prolonged half-life (8.68 vs 3.60 hours) and decreased clearance (0.294 vs 0.678 L/hr) compared to term infants 2.
Oral Dosing
Children Who Can Swallow Capsules
- Serious infections: 8-16 mg/kg/day divided into 3-4 equal doses 3
- More severe infections: 16-20 mg/kg/day divided into 3-4 equal doses 3
- Capsules must be taken with a full glass of water to avoid esophageal irritation 3
- For children unable to swallow capsules, use clindamycin palmitate oral solution 3
Pathogen-Specific Dosing from Guidelines
The 2011 IDSA/PIDS pediatric pneumonia guidelines provide specific dosing recommendations 4, 5, 4, 5:
For Staphylococcus aureus (MSSA)
- IV: 40 mg/kg/day every 6-8 hours
- Oral: 30-40 mg/kg/day in 3-4 doses
For MRSA (clindamycin-susceptible)
- IV: 40 mg/kg/day every 6-8 hours (preferred agent)
- Oral: 30-40 mg/kg/day in 3-4 doses (preferred agent)
For Group A Streptococcus
- IV: 40 mg/kg/day every 6-8 hours (alternative agent)
- Oral: 40 mg/kg/day in 3 doses (alternative agent)
For Streptococcus pneumoniae (resistant strains)
- IV: 40 mg/kg/day every 6-8 hours (may be effective)
- Oral: 30-40 mg/kg/day in 3 doses (alternative agent)
Important Clinical Considerations
Maximum doses: Oral doses should not exceed adult doses 4, 5. Single IM injections >600 mg are not recommended 1.
Dosing based on total body weight: Clindamycin should be dosed on total body weight regardless of obesity 1.
Duration for streptococcal infections: Continue treatment for at least 10 days in β-hemolytic streptococcal infections 1, 3.
Resistance monitoring: Clindamycin resistance is increasing in certain geographic areas among S. pneumoniae and S. aureus 4, 5, 4. Always verify local susceptibility patterns and perform D-test for inducible resistance in MRSA.
Drug interactions: When combined with rifampicin, clindamycin clearance increases 3-fold and oral bioavailability drops dramatically (from 56% to 4-11% depending on rifampicin dose). This combination should NOT be given orally; if necessary, use IV doses ≥3600-4800 mg/day 6.
Transition to oral therapy: Parenteral therapy may be changed to oral clindamycin when clinically appropriate 1. Recent data suggest 30 mg/kg/day oral dosing is effective for musculoskeletal infections in MRSA-prevalent communities, though 40 mg/kg/day remains the guideline recommendation 7.
Critical warning: Discontinue immediately if significant diarrhea occurs due to risk of Clostridioides difficile infection 1, 3.